KM Research Hub
← 返回论文库
部分完成 入排:排除 图源:可得 入排置信度 0.98

Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.

Nina Hertoghs, Sanne Roels, Matthias Brückner, Jerald Sadoff, Barbara L Banbury, Nicholas K Akers, Bryan Howie, Harlan S Robins, Griet A van Roey, Jeroen T B M Tolboom, Veronica V Rezelj, Jenny Hendriks, Hanneke Schuitemaker, Daniel J Stieh, Mathieu Le Gars

EBioMedicine 117 105809

PMID40517603
PMCIDPMC12278623
DOI10.1016/j.ebiom.2025.105809
发表日期2025-06-15
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: While vaccine-induced SARS-CoV-2 antibodies provide partial protection against COVID-19, a significant question remains regarding the role of vaccine-induced T cells in combating COVID-19. The purpose of this study is to investigate whether signatures of the T-cell response contribute to protection against (severe) COVID-19. METHODS: T cell receptor (TCR) sequencing was conducted using pre-vaccination and 29 days post-vaccination PAXgene samples from 396 participants in the phase 3 efficacy trial, ENSEMBLE. The dataset consists of 198 individuals who developed breakthrough COVID-19 infections, including 23 severe cases, and an equal number of matched control subjects. Immunosequencing and subsequent computational analysis was performed to identify SARS-CoV-2 and Spike-specific TCRs to quantify SARS-CoV-2 specific T cell breadth, depth, clonal expansion, and a model test score that describes magnitude of cellular response compared to pre-pandemic controls. FINDINGS: Preliminary analyses demonstrated high concordance and correlation between functional T cell responses measured by a standard intracellular cytokine staining and TCR sequencing metrics. Furthermore, vaccine-elicited T cell responses correlated inversely with the risk of developing severe COVID-19, while no strong relation was observed with overall symptomatic COVID-19 risk. A multivariable analysis including neutralizing antibody data and TCR scores indicated that, in addition to humoural responses, T cell responses contribute to protection against severe COVID-19. INTERPRETATION: Our findings show that higher vaccine-elicited T cell responses are significantly correlated with decreased risk of severe COVID-19, but not with risk of any symptomatic COVID-19. These results represent a direct correlation between vaccine-elicited T cell responses and protection from severe COVID-19. FUNDING: This work was fully funded by Janssen Vaccines & Prevention B.V. The samples were sourced from ENSEMBLE, which was partly funded by Biomedical Advanced Research and Development Authority (BARDA), under other transaction agreement HHSO100201700018C.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 3

Fig. 3 Univariate correlates of risk analysis for all cases vs. controls for COVID-19 and Spike scores (a) boxplots overlayed with individual data points of the Spike score (left) and the COVID-19 score (right) at D1 and D29, split between cases and controls in the ENSEMBLE trial. (b) Boxplots overlayed with individual data points of the COVID-19 Breadth and depth and Spike breadth and depth at D1 and D29, split between cases and controls. (c) Forest plots indicate Hazard Ratios (HR) per each standard deviation increase of the Spike and COVID-19 scores, 95% Confidence Intervals for the HR, and adjusted p-values (d) Cumulative probability of COVID-19 over the course of the study split by the upper, lower and middle tertile for the COVID-19 score (left) and the Spike score (right), with the 95% confidence intervals indicated by the dotted line.

COVID-19_Score

COVID-19

Fig. 3 · Panel COVID-19_Score

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel COVID-19_Score 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
Spike_score

COVID-19

Fig. 3 · Panel Spike_score

failed 待 EXE 对齐 预期 3 条 已提取 0 条

Panel Spike_score 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 0 条
No curves extracted
查看结果
其他 Figure(9,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Concordance between measurements of T cell responses at 29 days post vaccination (a) Boxplots overlayed with individual data points representing T cell responses induced by vaccination with a single dose of Ad26.COV2.S in the Phase 1/2a COV1001 trial, measured by intracellular cytokine staining (ICS) gated on T cells activated by a SARS CoV 2 Spike protein peptide pool in peripheral blood mononuclear cells, and by TCR sequencing-based COVID-19 and Spike scores. CD4+ T cell responses were characterized by the expression of interferon γ, interleukin 2, or both, without cytokines expressed by type 2 helper T (Th2) cells. CD8+ T cells were measured by the expression of interferon γ, interleukin 2, or both. (b) The COVID-19 score, and Spike score binary classifier calls were compared with the ICS responder status to calculate the percentage concordance between the assays. (c) Visualizations of the individual ICS data vs. the COVID-19 scores (upper panel) and the Spike scores (below panel) with Spearman correlation indicating the concordance between absolute ICS values and the COVID-19 scores and Spike scores over individual samples. Reported p-values are not corrected for multiplicity.
非 KM Figure
Fig. 2Fig. 2 COVID-19 Incidence across the three geographic regions over the course of the ENSEMBLE trial. The SARS-CoV-2 variants are assessed through viral genome sequencing, which is indicated by the different colours if sequencing data was available. Severe cases are depicted in triangles whereas the moderate-to-severe cases are indicated in circles.
非 KM Figure
Fig. 4Fig. 4 Univariate correlates of risk analysis for the severe vs. controls for COVID-19 and Spike scores (a) box plots representing the distribution of the Spike score and the COVID-19 score at D1 and D29, split between cases and controls. (b) Boxplots overlayed with individual data points of the COVID-19 Breadth and depth and Spike breadth and depth at D1 and D29, split between severe cases and controls. (c) Forest plots indicate HR for severe disease per each standard deviation increase of the Spike and COVID-19 scores, 95% Confidence Intervals for the HR, and adjusted p-values (d) Cumulative probability of severe COVID-19 over the course of the study split by the upper, lower and middle tertile for the COVID-19 score (left) and the Spike score (right), with the 95% confidence intervals indicated by the dotted line.
非 KM Figure
Fig. 5Fig. 5 Multivariable correlates of risk analysis for the COVID-19 and Spike scores and neutralizing antibody markers at Day 29. (a) Forest plots indicate HR for COVID-19 (all cases) per each SD increase of neutralizing antibody (nAb) markers combined with either the COVID-19 score (upper panel) or Spike score (lower panel) at D29, 95% CI and p-value. (b) Forest plots indicate HR for severe COVID-19 per each SD increase of nAb markers combined with either the COVID-19 score (upper panel) or Spike score (lower panel) at Day 29, 95% CI and unadjusted p-value.
非 KM Figure
Supplementary Figure S1Supplementary Figure S1 TCR sequencing metrics shown in all ENSEMBLE trial participants at D1 and D29 . COVID-19 and Spike scores (upper panel), COVID-19 breadth and Spike score-based breadth (middle panel. COVID-19 and Spike score-based depth (lower panel).
非 KM Figure
Supplementary Figure S2Supplementary Figure S2 Univariate correlates of risk analysis for all cases vs. controls for expansion of TCR clones . Boxplots overlayed with individual data points of the total number of expanded clones between D1 and D29 and newly detected expanded clones at D29, split between cases and controls in the ENSEMBLE trial.
非 KM Figure
Supplementary Figure S3Supplementary Figure S3 Univariate correlates of risk analysis for the cases vs. controls for COVID-19 and Spike score-based TCR metrics . Boxplots overlayed with individual data points of the COVID-19 Breadth and depth and Spike breadth and depth at D1 and D29, split between moderate cases, severe cases, and controls. Total number of expanded clones between D1 and D29 and newly detected expanded clones are shown in the lower panel. Adjusted p-values are added.
非 KM Figure
Supplementary Figure S4Supplementary Figure S4 Multivariable correlates of risk analysis for the COVID-19 and Spike scores and binding antibody markers at Day 29 . (a) Correlation plots show high correlation between TCR metrics and between humoural markers (b) Forest plots indicate HR for all BTI per each SD increase of binding antibody (bAb) markers combined with either the COVID-19 TCR score (upper panel) or Spike score (lower panel) at D29. (c) Forest plots indicate HR for all COVID-19 (all cases) per each SD increase of bAb markers combined with either the COVID-19 TCR score (upper panel) or Spike score (lower panel) at D29 specifically for severe cases. 95% Confidence Intervals for the HR, and p-values based on the Cox model are shown. The multivariate analyses were not corrected for multiplicity.
非 KM Figure
Supplementary Figure S5Supplementary Figure S5 Summary forest plot combining univariate and multivariable correlates of risk analysis for the COVID-19 and Spike scores and antibody markers at Day 29.
非 KM Figure